Clinical trial results published for Cold Atmospheric Plasma treating Actinic Keratoses
By: Adtec Europe Ltd
Actinic keratoses (AK) represent the most common skin malignancy worldwide and are considered the earliest stage in cutaneous squamous cell carcinoma development. Conventional therapies bear significant side effects and/or are limited to small treatment areas. Thus, there is a continuing need for nontoxic lesion- and field-directed treatment options for extensive AK. Cold atmospheric plasma (CAP) is a partially ionized gas containing a mixture of reactive oxygen and nitrogen species. In addition to its well documented antimicrobial properties, growing evidence points to antitumor effects.
The clinical trial tests the difference in clinical efficacy of our Adtec SteriPlas medical device vs Diclofenac 3% gel for the treatment of actinic keratoses lesions in a total of 60 patients, aged between 56-91 years of age.
Cold atmospheric plasma treatment with the Adtec SteriPlas showed significantly better effectiveness over diclofenac in reducing the actinic keratoses lesion count. Unlike Diclofenac, cold atmospheric plasma showed no major side effects during the study. Thus, this modality might be especially well-suited for patients who require nontoxic treatment options, particularly immunocompromised patients and those with extensive field cancerization. This continues to be one of our strongest and most favoured characteristics of the Adtec SteriPlas: no side effects.
We encourage you to read the clinical trial publication and welcome any questions that you have.